Quantitative observational evidence of indirect herd benefits from COVID-19 vaccination or prior infection on SARS-CoV-2 infections and COVID-19 deaths: a population-based retrospective cohort study in Ontario, Canada
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Empirical evidence on the indirect herd benefits of COVID-19 vaccination and/or prior infection is limited. We aimed to examine how area-level immunity interacts with individual-level immunity to affect COVID-19 diagnoses and deaths.
Methods
Ontario residents aged ≥18 years were followed from August-01-2021 to January-30-2022. Individual-level immunity was defined as received a primary series of COVID-19 vaccines or a positive SARS-CoV-2 test in the past 165 days. Area-level immunity was determined based on the proportion of immune individuals in an individual’s residing area. We used logistic regression and cause-specific hazard models to examine the relationship between immunity and COVID-19 diagnosis, and between immunity and COVID-19 death, respectively. We included an interaction term between individual-level and area-level immunity in each model.
Results
Of 11,122,816 adults, 7,518,015 (67.6%) were immune at baseline. After accounting for individual-level demographics, baseline health, and area-level social determinants of health, area-level immunity (highest vs. lowest quintiles) was associated with lower odds of COVID-19 diagnosis; the association was larger among non-immune (odds ratios [95% confidence interval]: 0.72 [0.70, 0.75]) than immune individuals (0.93 [0.90, 0.96]). Higher area-level immunity (highest vs. lowest quintiles) was also associated with lower hazard of COVID-19 death among non-immune individuals (hazard ratio: 0.77 [0.60, 1.00]).
Conclusions
Our study provides observational evidence supporting the herd benefits of vaccination or prior infection on SARS-CoV-2 infections and COVID-19 deaths. Findings reinforce the need for high vaccination coverage to protect vaccinated and unvaccinated populations, while providing insights for interpreting vaccine effectiveness estimates in the context of herd immunity.
Main points
Using area-level immunity coverage as a proxy for herd immunity, our study demonstrates observational evidence of indirect herd benefits from vaccination and/or prior infection on SARS-CoV-2 infections and COVID-19 deaths. Moreover, herd benefits are greater among non-immune individuals.
